A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis

Study Purpose:

The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling.

The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.

Study Status:

Not recruiting


Amyotrophic Lateral Sclerosis , Sialorrhea

Study Type:


Type of Intervention:

Drug, Procedure

Intervention Name:

Botulinum toxin type B (Myobloc), Injection of salivary glands



Phase 2/Phase 3

Study Chair(s)/Principal Investigator(s):

Carlayne E Jackson, MD, The University of Texas Health Science Center at San Antonio, Charles B Simpson, MD, The University of Texas Health Science Center at San Antonio

Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

United States

Full Study Summary:

The secondary goals of this study are to:

- determine the safety of bilateral injections of Myobloc into the parotid and submandibular glands as an effort to control sialorrhea;

- determine by objective measures if the Myobloc injection decreases the saliva produced;

- determine caregiver perceived benefit from Myobloc injection.

Study Sponsor:

The University of Texas Health Science Center at San Antonio

Estimated Enrollment:


Estimated Study Start Date:

06 / 30 / 2003

Estimated Study Completion Date:

08 / 01 / 2007

Posting Last Modified Date:

03 / 14 / 2012

Date Study Added to neals.org:

07 / 29 / 2005

Minimum Age:

21 Years

Maximum Age:

85 Years

Inclusion Criteria:

- Diagnosis of probable or definite ALS based on current World Federation of Neurology criteria

- Between the ages of 21-85, inclusive

- Sialorrhea refractory to treatment with at least two anticholinergic medications OR has been intolerant of anticholinergic medications due to side effects

- Capable of giving informed consent

- Must be able to attend all study visits

Exclusion Criteria:

- Patient has any uncontrolled significant medical, psychiatric or neurological disease (other than ALS) over the past 30 days

- History of ongoing substance abuse

- History of non-compliance with treatment in other experimental protocols

- Cannot provide informed consent or comply with evaluation procedures

- Has received any form of botulinum toxin in the past for any indication

- Women who are pregnant, lactating, or of child bearing potential not using an adequate form of birth control

- Currently being treated with coumadin

- Forced vital capacity (FVC) <40% of predicted unless the tidal volume is > 600cc, as patients with significant bulbar weakness may show a falsely low FVC due to bulbar muscle spasticity

University of Kansas Medical Center/Neurology, 1008 Wescoe

Kansas City, Kansas 66160-7314
United States

Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 1540 Garden Terrace

Charlotte, North Carolina 28203
United States